Proscribe sold to Envision Pharma Group

APAC-based medical communications specialist ProScribe has been acquired by innovative scientific communications and technology company, Envision Pharma Group, in a transaction managed by BCMS.

Led by Professor Karen Woolley and Dr Mark Woolley, ProScribe is a provider of Medcomms services to pharmaceutical, biotechnology, device and academic organisations, with a specialism in clinical trials submissions. Founded in 2000, ProScribe has a strong presence in the Asia-Pacific (APAC region), with offices across Australia, as well as Shanghai and Tokyo.

“We valued the expert guidance that BCMS provided – we always felt our business, our staff, and our aspirations were in safe hands” – Professor Karen Woolley, Proscribe

The acquirer, UK-headquartered Envision Pharma Group, is a scientific communications and technology company, focused on the life sciences industry. Operating internationally from sites in the USA and UK, the group is also an industry leader in medical publication planning, execution, consultancy, and technology.